SEC Form 4 · accession 0000899243-17-002127
Seres Therapeutics, Inc. · MCRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Wael Hashad
Officer — EVP & Chief Commercial Officer
Period of report
Jan 26, 2017
Accepted (ET)
Jan 27, 2017 · 5:56 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609809
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $9.89 | Jan 26, 2017 | A | 75,000 | A | — | Jan 25, 2027 | Common Stock | 75,000 | 75,000 | D |
| Restricted Stock UnitsF2,F3 | — | Jan 26, 2017 | A | 25,000 | A | — | — | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1The option will vest as to 25% of the shares on January 26, 2018. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
- F2Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- F3These restricted stock units vest as to 20% on January 26, 2018, 30% on January 26, 2019 and 50% on January 26, 2020.
Remarks
Exhibit List Exhibit 24 - Power of Attorney